Asim A Shah, M.D.
Picture
Asim A Shah, M.D.
Professor & Executive Vice Chair
Positions
- Professor & Executive Vice Chair
-
Menninger Dept of Psychiatry
Baylor College of Medicine
Houston, Texas United States
- Barbara & Corbin Robertson Jr. Endowed Chair in Psychiatry
-
Menninger Dept of Psychiatry
Baylor College of Medicine
United States
- Chief/Division of Community Psychiatry
-
Menninger Dept of Psychiatry
Baylor College of Medicine
United States
- Professor
-
Community and Family Medicine
Baylor College of Medicine
- Chief of Psychiatry
-
Harris Health System & Ben Taub Hospital
- Director
-
Mood Disorder Research Program at Harris Health System & Ben Taub Hospital
- Director
-
Community Behavioral Health Program, Harris Health System
United States
- Executive Director
-
Psychotherapy Services, Ben Taub Hospital
- Chair
-
Mental Health America of Greater Houston
United States
- Appointed
-
Texana Center Board of Trustees, Fort Bend Commissioners Court, Representing No. 4, Fort Bend County
Rosenberg, Texas United States
Addresses
- Neuropsychiatric Center (Hospital)
-
Room 2.125
Houston, TX 77030
United States
Phone: (713) 873-5270
aashah@bcm.edu
Education
- Residency at Delaware State Hospital
- 01/1999 - New Castle, Delaware United States
- MBBS from Dow Medical College, University of Karachi
- 01/1991 - Karachi, Pakistan
Certifications
- American Board of Psychiatry and Neurology, Inc
- Fellow
- American Psychiatric Association
Professional Statement
Dr. Shah is the Executive Vice Chair and Professor in the Menninger Department of Psychiatry and Behavioral Sciences, and the Department of Community and Family Medicine, Baylor College of Medicine. In September 2016, Dr. Shah was appointed as the Inaugural Vice Chair for Community Psychiatry, which has now become the Division of Community Psychiatry under his leadership as its Chief. He is also Chief of Psychiatry for Ben Taub Hospital/Harris Health System and the Director of Community Behavioral Health Program for Harris Health System. His service is the largest outpatient Mental Health provider in Harris County, with over 100,000 visits a year. He is also the Director of Mood Disorder Research Program at Ben Taub and the Executive Director of Psychotherapy Services for Ben Taub Hospital. Dr. Shah has done numerous media presentations to National and International Radio/TV/Newspapers on topics like Ketamine and Depression, Election stress, mass shootings, stress management, work related stress, ADHD, road rage, seasonal affective disorder and Phobias and has widely presented both nationally and internationally. He has received two Fulbright and Jaworski Awards, one for Teaching and Evaluation in 2012 and second for Educational Leadership in 2014. He also received Rising Star Clinician Award from Baylor in 2014. His current research is in the field of treatment resistant depression, and ketamine.He won the Faculty of the Year Award in 2013 from Baylor¹s Psychiatric Residency Program, and in 2014 from Baylor¹s Psychology Internship Program, and also was named by Houstonia magazine in their Top Doctors list for Houston in 2013, 2014, 2015 and 2017, and Top Doctors of Houston Award by Castle Connolly in 2017. He was appointed as Board Director for Mental Health America (MHA) in June 2017.
Websites
Professional Development
- Efficaciousness of mental health outreach in religious settings
- Conference (Presenter, 2010)
- Sponsor: Association of Academic Psychiatry’s Annual Meeting
- Gupta V, Shah AA, Singh H, Coverdale J, Harris T. (Poster Presentation) September 2010.
- Bupropion Induced Bruxism
- Conference (Presenter, 2011)
- Sponsor: American Psychiatric Association’s Annual Meeting
- Singh H, Shah AA, Gupta V, Wadha R. (Poster Presentation)
- Efficaciousness of mental health outreach in religious settings
- Conference (Presenter, 2011)
- Sponsor: Association of Medicine and Psychiatry’s Annual Meeting
- Gupta V, Shah AA, Singh H, Coverdale J, Harris T. Poster Presentation
- Bupropion Induced Bruxism
- Conference (Presenter, 2011)
- Sponsor: Association of Medicine and Psychiatry’s Annual Meeting
- Singh H, Shah AA, Gupta V, Wadha R. Poster Presentation
- Risperidone Induced Hyperprolactinemia
- Conference (Presenter, 2011)
- Sponsor: Association of Medicine and Psychiatry’s Annual Meeting
- Shah AA, Gupta V, Wadha R. Poster Presentation
- Caffeine Induced QTc Prolongation
- Conference (Presenter, 2011)
- Sponsor: Association of Medicine and Psychiatry’s Annual Meeting
- Shah AA, Gupta V, Wadha R. (Poster Presentation)
- Risperidone Induced Hyperprolactinemia
- Conference (Presenter, 2011)
- Sponsor: Institute on Psychiatric services
- Shah AA, Gupta V, Wadha R. (Poster Presentation)
- Paliperidone Induced Hyperprolactinemia
- Conference (Presenter, 2011)
- Sponsor: Institute on Psychiatric services
- Wadha R, Gupta V, Shah AA. Poster Presentation
- Improvements in Citalopram Sexual Dysfunction by Switching to Escitalopram.
- Conference (Presenter, 2012)
- Sponsor: APA’s 165th Annual Meeting
- Avellaneda AA, Lopez L, Shah AA. (Submission ID Number 34426)
- Psychiatry Resident Training in Screening, Brief Intervention, and Referral to Treatment for Alcohol and Substance Use Disorders
- Conference (Presenter, 2013)
- Sponsor: 66th Annual APA meeting
- Shah AA, Martin CD, Bray JH, Kowalchuk A, Waters V, Laufman L, Shilling EH, Lopez Y III, May 19, 2013.
- Psychiatry Resident Training in Screening, Brief Intervention, and Referral to Treatment for Alcohol and Substance Use Disorders
- Conference (Presenter, 2013)
- Sponsor: 65th Institute of Psychiatric Services
- Shah AA, Martin CD, Bray JH, Kowalchuk A, Waters V, Laufman L, Shilling EH, Lopez Y III, October 12, 2013.
- Implementation of Scheduled Medication Policy in Psychiatric Emergency Center Admissions
- Conference (Presenter, 2013)
- Sponsor: 65th Institute on Psychiatric Services
- Moukaddam N, Matorin A, Shah AA, October 10-13, 2013.
- Development of a Standardized Medical Clearance Form for a Psychiatric Emergency Center
- Conference (Presenter, 2013)
- Sponsor: 65th Institute on Psychiatric Services
- Moukaddam N, Shah AA, Matorin A, Horton C, October 10-13, 2013
- Addressing systematic barriers in access to care for Bhutanese refugees in Houston: Experience from the Refugee Health & Leadership Academy
- Conference (Presenter, 2014)
- Sponsor: 167th Annual Meeting of American Psychiatric Association
- Cai C, Banu S, Moukaddam N, Pilgrim P, Champlin M, Shah AA., May 3-7, 2014
- Crossing Cultural Borders: A Resident Training Curriculum to Address the Needs of Refugees
- Conference (Presenter, 2014)
- Sponsor: Association of Academic Psychiatry
- Asghar-Ali AA, Banu S, Jani S, Melton B, Shah AA. , September 17-20, 2014
- Is it Ethical to use Valproate (Category D) in Women of child bearing Age?
- Conference (Presenter, 2014)
- Sponsor: 66th Institute on Psychiatric Services
- Shah AA, Wadhwa R, Gupta V, Contreras VM. October 30-November 2, 2014
- Integrating Licensed Chemical Dependency Counseling Services Into Psychiatric Emergency Center
- Conference (Presenter, 2014)
- Sponsor: 66th Institute on Psychiatric Services
- Moukaddam N, Shah AA, Matorin A, Aoshima A. October 30-November 2, 2014
- Addressing Systematic Barriers in access to care for Bhutanese refugees in Houston: Experience From the Refugee Health & Leadership Academy
- Conference (Presenter, 2014)
- Sponsor: 66th Institute on Psychiatric Services
- Cecilia Cai, BS Sophia Banu MD, Nidal Moukaddam MD, Petra Pilgrim, MD Marie Champlin MD, Asim Shah MD, October 30-November 2, 2014. (encore poster)
- What is New in Medical Clearance: Real-life Examples at the Confluence of Psychiatric and Emergency Care
- Conference (Presenter, 2014)
- Sponsor: 5th Annual National Update on Behavioral Emergencies
- Moukaddam N, Tucci V, Matorin A, Shah AA. December 10-12, 2014
- Culturally Competent Psychiatry for Refugees: A Pilot Program of a Standardized Mode
- Conference (Presenter, 2015)
- Sponsor: Annual Meeting Society for the Study of Psychiatry and Culture
- Dinh, Jani SN, Banu S, Du Y, Shah AA. April 23-25, 2015.
Selected Publications
- Shah A, Mathew S "An Update on New Medications for the Treatment of Major Depressive Disorder." New Directions in Psychiatry. 2015;34(3):159-170.
- Murrough JW, Iosifescu DV, Chang LC, Al Jurdi RK, Green CE, Perez AM, Iqbal S, Pillemer S, Foulkes A, Shah AA, Charney DS, Mathew SJ. "Antidepressant Efficacy of Ketamine in Treatment-Resistant Major Depression: A Two-Site Randomized Controlled Trial." Am J Psychiatry. 2013 Oct;(170):1134-1142.
- Shah AA, Awais Aftab, Coverdale J "Review article, "QTc Prolongation with Antipsychotics: Is Routine EKG Monitoring Recommended?"." J Psychiatric Practice.;
- Mathew SJ, Shah A, Lapidus K, Clark C, Jarun N, Ostermeyer B, Murrough JW. Ketamine for Treatment-Resistant Unipolar Depression CNS Drugs: 1 March 2012 - Volume 26(3), pp 189-204 "Ketamine for Treatment-Resistant Unipolar Depression." CNS Drugs. 2012 Mar 1;26(3):189-204.
- Shah A "Update on DSM V." Pakistan Journal of Medical Students. 2012 Feb 22;2(2)
- Singh H, Shah AA, Gupta V, Coverdale J, Harris T. "Efficaciousness of Mental Health Outreach in Religious Settings." Am J Psychiatric Rehabilitation. 2012 Aug;15:290–298.
- Owusu Y, Kunik M, Coverdale J, Shah AA, Primm A, Harris T. "Lessons Learned: A Homeless Intervention By a Medical Student Academic Psychiatry." 2012 May 1:36(3):.. 2012 May 1;36(3):219-222.
- Shivnaveen Bains and Asim A. Shah "Review Article--Sexual Side Effects of Antipsychotic Drugs." Adv Pharmacoepidem Drug Safety. 2012 May 10;1:2.
- Murrough JW, Iosifescu DV, Chang LC, Al Jurdi RK, Green CM, Iqbal S, Pillemer S, Perez AM, Foulkes A, Shah AA, Charney DS, Mathew SJ "Antidepressant Efficacy of Ketamine in Treatment-Resistant Major Depression Established in a Two-Site, Randomized, Controlled, Parallel-Arm Clinical Trial." ;
- Shah AA "Novel Approaches to Treatment Refractory Depression; An Overview." Psychiatric Annals. 2016;46(4):220-222.
- Moukaddam N, Shah AA "TRD an Overview." Psychiatric Annals. 2016;46(4):224-229.
- Hashmi AM, Khawaja I, Shah AA "Management of Treatment Resistant Depression in a young male: Complicated and challenging." Psychiatric Annals. 2016;46(4):216-219.
- Tamez J, Du YB, Shah AA "Management of Treatment Resistant Depression in Intensive Outpatient Programs." Psychiatric Annals. 2016;46(4):236-239.
- Ostermeyer B, Flores A, Duke C, Shah AA "Medical Decision-Making Capacity in Depression." Psychiatric Annals. 2016;46(4):247-252.
- Shah AA "Overview of Neurocognitive Disorders." Psychiatric Annals. 2016;46(2):89-91.
- Shah AA, Aftab A "Should physicians prescribe antipsychotics in dementia?." Psychiatric Annals. 2016;46(2):97-102.
- Scott JG, Ostermeyer B, Shah AA "Neuropsychological Assessment in Neuro-Cognitive Disorders." Psychiatric Annals. 2016;46(2):118-126.
- Jones KC, Han JY, Shah AA "The Cognitive Impairment Continuum: Areas of Controversy with use of Cognitive Enhancers." Psychiatric Annals. 2016;46(2):110-117.
- Moukaddam N, Bejjani C, Shah AA "Treatment Approaches to Neurocognitive Disorders." Psychiatric Annals. 2016;46(2):103-109.
- Clionsky LN, Matorin A, David EH, Coverdale JH, Shah AA "Medical Capacity and Competency in a Geriatric Population: Case Example Related to Self-Care and Placement." Psychiatric Annals. 2016;46(2):127-131.
- Imran S. Khawaja IS, Jean-Noel F, Shah AA "Polypharmacy as a cause of fall and worsening of RLS in an elderly woman." Psychiatric Annals. 2016;46(2):86-88.
- Raythatha A, Shah A, Tucci V, Moukaddam N "Synthetic Cannabinoids and Dysphonia: A Case Report." J Gen Practice. 2016;4:220.
- Moukaddam N, Shah A "From Dementia to Neurocognitive Disorders: DSM-5 Changes." New Directions in Psychiatry. 2015;35(4):263-278.
- Hashmi A, Shah A "Depression: An Overview and Diagnostic Changes in the DSM-5." New Directions in Psychiatry. 2015;35(4):247-260.
- Shah A, Aftab A, Latorre S "Psychiatric Disorders and Psychotropic Treatment in the Postpartum Period." New Directions in Psychiatry. 2015;35(3):229-245.
- Wilson M, Nordstrom K, Shah A, Vilke GM "Psychiatric Emergencies in Pregnant Women." Emerg Med Clin NAM. 2015;33(4):841–851.
- Nathan SD, Hong M, Matorin A, Shah A "Stabilization and Management of the Acutely Agitated or Psychotic Patient." Emerg Med Clin NAM. 2015;33(4):739–752.
- Halmer T, Dark C, Beall R, Shah A "Policy Considerations in Behavior Health Emergencies." Emerg Med Clin NAM. 2015;33(4):875–891.
- Tran M, Kuo D, Matorin A, Shah A "Depression and Suicidal Patient." Emerg Med Clin NAM. 2015;33(4):875–891.
- Aftab A, Shah AA, Hashmi AM "Pathophysiological Role of HERV-W in Schizophrenia." Journal of Neuropsychiatry and Clinical Neuro. 2016;28(1):17-25.
- Shah AA, Banu S, McMorris R, Anandan S "Intellectual Disability Disorder (IDD): from the DSM-IV-TR to the DSM-5.." New Directions in Psychiatry. 2016 Oct;36:193-206.
- Tucci V, Moukaddam N, Patel N, Laufman L, Shah AA, Peacock WF "Epic Fail! Poor Neuropsychiatric Documentation Practices in Emergency Psychiatric Patients." Emergency Medicine. 2016 Jul;6(4)
- Moukaddam N, Tucci V, Galwankar S, Shah AA "In the Blink of An Eye: Instant Countertransference and Its Application in Modern Healthcare." J Emerg Trauma Shock. 2016;9:95-96.
- Jani S, Johnson RS, Banu S, Shah S "Cross-Cultural Bias in the Diagnosis of Borderline Personality Disorder." Bull Menninger Clin. 2016;80(2):146-165.
- Shah, A, Han J "Anxiety Disorders:Subtypes, Diagnosis, Treatment and Neurological Comorbidities." CONTINUUM: Lifelong Learning in Neurology. 2015;21(3):772-782.
- Lee S, Tucci V, Moukaddam N, Worley A, Shah AA "Pregnant and abandoned: the multiple hurdles of medically clearing and admitting a pregnant patient to an inpatient psychiatric unit.." Journal of Psychiatry and Mental Health. 2016;1
- Shah AA, Aftab A "Are Psychotropic Drugs Safe to use During Lactation?." Psychiatric Annals. 2015 Feb;45(2):77-82.
- Shah, A "Women's Issue." Psychiatric Annals. 2015;45(2):68-69.
- Shah A, Khawaja IS, Aftab A "Are Psychotropics Drugs Safe to Use During Pregnancy?." Psychiatric Annals. 2015 Feb;45(2):71-76.
- Tucci V, Liu J, Matorin A, Shah A, Moukaddam N "Like the Eye of the Tiger: Exclusionary Criteria as Administrative Obstacles in the Medical Clearance Process." Emergency Psychiatry (in review). 2016;
- Tucci V, Moukaddam N, Matorin A, Shah A, Onigu-Otite E, Santillanes "Eenie, meenie, miney, moe: Inpatient Psychiatric Facility Exclusionary Criteria and the Emergency Pediatric Psychiatric Patient." Int J Acad Med (submitted). 2016;
- Worley A, Moiz S, Moukaddam N, Tucci V, Shah A, Wilson M. "Depression and Pregnancy." Medical J of Ob Gyn (submitted). 2016 Jun;
- Moukaddam N, Mathai D, Matorin A, Shah A "Paradoxical Increase in Synthetic Cannabinoid Emergency-Related Presentations After City Wide Ban: Lessons From Houston, Texas." Bull Menninger Clin (accepted). 2016 Aug;
- Moukaddam N, Moiz S, Worley A, Shah A, Tucci V "Teratogenic Potential of Commonly Prescribed Psychotropic Drugs." Med J Ob Gyn (in progress). 2016;
- Medford-Davis L, Moukaddam N, Laufman, Matorin A, Shah A, Tucci V "True Costs of Medical Clearance: Accuracy and Disagreement Between Psychiatry and Emergency Medicine." Emergency Medicine J (submitted). 2016;
- 5. Matorin A, Shah Asim, Ruiz Pedro "Clinical Manifestations of Psychiatric Disorders." Kaplan & Sadock's Comprehensive Textbook of Psychi. 2017;
- Iqbal SZ, Salami T, Reissinger MC, Masood HM, Ukrani K, Shah A. "The Mental Health Clinician’s Role in Advocacy for Survivors of Human Trafficking: Treatment and Management.." Psychiatr Ann. 2021;51(8):373-377.
- Banu S, Saunders J, Conner C, Blassingame J, Shah AA "Mental Health Consequences of Human Trafficking." Psychiatr Ann. 2021;51(8):369-372.
- Moukaddam N, Torres M, Vujanovic AA, Saunders J, Le H, Shah AA "Epidemiology of Human Trafficking." Psychiatr Ann. 2021;51(8):359-363.
- Shah AA "Guest Editorial, Human Trafficking and the Role of Clinicians." Psychiatr Ann. 2021;51(8):356-357.
- Li BT, Avellaneda-Ojeda A, Le H, Iqbal SZ, Zaheer M, Naqvi MF, Shah A "Caffeine Use Disorder: Do not Sleep on It." 2021;41(1):47-63.
- Le H, Roca JA, Chaudhry HW, Vyas A, Shah A "Addiction and Motivation to Stay Sober." Directions in Psychiatry. 2021;41(1):31-46.
- Saunders J, Dongarwar D, Salemi J, Schulte J, Persse D, Matin A, Banu S, Shah A "Emergency Mental Health Calls to First Responders Following a Natural Disaster: Examining the Effects from Hurricane Harvey." Int J Acad Med. 2021;7(1):22-29.
- Saleh A, King M, Hamilton J, Pigott T, Elkhatib R, Shah A, Selek S "Birth Seasonality of Schizophrenia and Bipolar Disorder? A Review of Inpatient Records." Journal of Affective Disorders. 2021;287:15-18.
- Chen EY, Robichaux K, Gordon MR, Coverdale JH, Shah AA, Davis MP, Nguyen PT "A Pilot Program’s Healthcare Response to Human Trafficking in Houston, Texas." Journal of Human Trafficking. 2021;
- Saraykar S, Shah AA, Rashid A "Psychiatric Consultations from an Oncology Perspective: Medical Students’ Clerkship Experience at a Comprehensive Cancer Center." Directions in Psychiatry. 2020;40(4):305-315.
- Naqvi MF, Iqbal SZ, Le H, Nathani K, Shah AA "Neuropsychiatric Complications of COVID-19." Directions in Psychiatry. 2020;40(4):263-273.
- Le H, Zhou H, Nguyen B, Shah AA "A Review of the Impact of Wearing Masks on COVID-19 Transmission and the Psychology behind Resistance to Wearing Masks." Directions in Psychiatry. 2020;40(4):249-262.
- Asuzu K, Inikori O, Onigu-Otite E, Shah AA "Sports Related Concussions in High School Athletics." Directions in Psychiatry. 2020;40(3):229-248.
- Abbas S, Yasmin A, Maqbool N, Shah AA and Fariq A "Insights into the microbiological and virulence characteristics of bacteria in orthopaedic implant infections: A study from Pakistan.." PLoS One. 2023 Oct 17;18(10) Pubmed PMID: 37847701
- Goetz A, Kennedy S, Kook M, Guzick A, Amos Nwankwo G, Hana L, Schneider S, Cepeda S, Weinzimmer S, Shah A, Goodman W, Salloum A, Ehrenreich-May J, and Storch E "Examining the Effectiveness of the Transdiagnostic Unified Protocol for Emotional Disorders Delivered to Youth Following Hurricane Harvey.." Child & Youth Care Forum. 2023;52(6):1413-1429.
- Asadi LK and Shah AA "Gender bias in antidepressant direct-to-consumer pharmaceutical advertising." Comprehensive Psychiatr. 2023;123::152384 doi.org/10.1016/j.comppsych.2023.152384.
- Iqbal S, Han J, Matorin A, Husnain A, Ullah U, Naeem R, Shah A. "Schizophrenia and Chronic Psychotic Disorders: Update on Treatment Options and New Trends." Psychiatric Annal. 2023;53(4):155-159.
- Shah, A "Psychosis and its Manifestations." Psychiatric Annal. 2023;53(4)
- Shah, AA and Iqbal, SZ "Recent Advances in Psychopharmacology: From Bench to Bedside Novel Trends in Schizophrenia.." J Pers Med. 2023 Feb;13(3):411.
- Shah AA "Mental Health & COVID 19: Where are we in 2022?." J Dow Univ health Sci. 2022;16(1):1-2.
Memberships
- American Psychiatric Association, 2000 - present
- Member
- National Network of Depression Centers (NNDC)
- Member (03/2011)
- American College of Psychiatrists
- Member (10/2014)
Funding
- Esketamine
- $200,000.00 (05/24/2019 - 06/05/2020) Johnson & Johnson
- An Open-Label Long-Term Extension Safety Study of Intranasal Esketamine in Treatment Resistant Depression BCM IRB Protocol # H-38977
- Triad Rollover - #BCM IRB #H-45882
- $102,845.00 (05/23/2019 - 05/23/2021) Avanir
- A Phase 3, Multicenter, Long-Term, Extension Study of the Safety and Efficacy of AVP-786 (Deuterated [D6] Dextromethorphan Hydrobromide [D6-DM]/Quinidine Sulfate [Q]) for the Treatment of Agitation in Patients with Dementia of the Alzheimer’s type.
- Monarch Study - #BCM IRB #H-45628
- $88,370.00 (03/30/2019 - 02/22/2021) Otsuka
- A Phase IIIB Multicenter, Open-Label, Mirror-Image, Trial in Adult Subjects with Schizophrenia Treated Prospectively for 6 months with Abilify Mycite®
- ALKS3831- A304
- $275,568.00 (03/17/2019 - 03/21/2020) Alkermes
- A Phase 3, Multicenter Study to Assess the Long-Term Safety and tolerability of ALKS 3831 in subjects with Schizophrenia. BCM IRB Protocol # H-41659
- ACP-103-059 - #Brain IRB #H-45200
- $370,062.00 (02/18/2019 - 02/18/2020) Acadia
- A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled study to Evaluate the Efficacy and Safety of Adjunctive Pimavanserin in Subjects with Major Depressive Disorder and Inadequate Response to Antidepressant Treatment
- ACP-103-055 - #Brain IRB # H- 45584
- $357,426.00 (02/18/2019 - 02/18/2020) Acadia
- A 52-Week Open-Label Extension Study of Pimavanserin in Subjects with Major Depressive Disorder and Inadequate Response to Antidepressant Treatment
- ALKS3831- A307 - #BCM IRB Protocol # H-43721
- $101,502.00 (02/10/2021 - 03/08/2022) Alkermes
- A Study to evaluate the effect of ALKS 3831 compared to Olanzapine on body weight in young adults with the Schizophrenia, Schizophreniform, or Bipolar I. Disorder I who are early in their illness.
- Triad Study - #BCM IRB Protocol # H-41658
- $309,501.00 (02/13/2019 - 02/18/2020) Avanir
- A Phase 3, Multicenter, Randomized, Double- Blind, Placebo- Controlled Study to assess the efficacy, safety, and tolerability of AVP-786 (Deuterated[D6]- Dextromethorphan Hydrobromide [D6- DM]/Quinidine Sulfate[Q]) for the treatment of Agitation in patients with Dementia of the Alzheimer’s type.
- Elevate Study - #BCM IRB Protocol # H-42979
- $188,838.00 (01/08/2019 - 01/08/2020) VistaGen
- Double -Blind, Placebo- Controlled, Phase 2 Trial to test efficacy and safety of AV-101(L-4-Chlorokynurenine) as adjunct to the current antidepressant therapy in patients with Major Depressive Disorder (MDD) with an inadequate response to current antidepressant.
- Burnout in Residents – BCM. Can a Smartphone App Help Tracking and Identification? (07/27/2018 - 07/11/2020) BCM IRB # H-38973
- ALK3831 – A308 – - #BCM IRB # H-44153
- $150,480.00 (11/27/2018 - 08/22/2022) Alkermes
- A Phase 3, Multicenter Study to Assess the Long-Term Safety and Tolerability of ALKS 3831 in Subjects with Schizophrenia
- Mechanisms, Prediction and Treatment of Short-Term Risk for Suicidal Behavior, Version 2 - American Foundation for Suicide Prevention (07/17/2018 - 06/10/2020) BCM IRB # H-38275
- MDD2002
- $231,604.00 (07/12/2018 - 08/09/2020) Johnson & Johnson
- A 6-Month, Multicenter, Double- Blind, Randomized, Flexible-Dose, Parallel-Group study to compare the efficacy, safety, and tolerability of JNJ-42847922 Versus Quetiapine Extended- Release as adjunctive therapy to antidepressant in adult subject with Major Depressive Depression Disorder who have responded inadequately to antidepressant therapy. BCM IRB Protocol # H-42671
- Esketamine
- $1,440,000.00 (01/11/2016 - 08/31/2017) BCM IRB Protocol # H-37181
- PI - A Randomized, Double Blind, Multicenter, active-controlled study of intra nasal plus an oral antidepressant for relapse prevention in Treatment resistant depression
- OBSERVEMDD0001
- $199,890.00 (12/08/2014 - 01/19/2017) H-35911
- PI - A Prospective, Longitudinal, Observational Study to Evaluate Potential Predictors of Relapse in Subjects with Major Depressive Disorder Who Have Responded to Antidepressant Treatment
- Does countertransference in providers affect medical decision making (11/24/2014 - 08/03/2016) H-35120
- Co-PI - Screening and long- term 5 year naturalistic cohort study collecting clinical data on subjects with primary mood disorders
- Corcept C-1073-14
- $88,917.00 (04/17/2013 - 07/07/2014) BCM IRB Protocol # H-32760
- PI, Study to Confirm a Diagnosis of Major Depressive Disorder with Psychotic Features and Screen Potential Patients. Phase 3 double blind study designed to assess the use of mifepristone and its effects on the HPA axis thus reducing psychotic symptoms in patients with Psychotic Depression.
- SBIRT Resident Teaching Grant
- $75,000.00 (02/01/2010 - 09/30/2014) Faculty Champion
- To educate and train internal medicine, family practice, psychiatry and pediatrics residents from internship to screen, evaluate and manage patients with substance use (SBIRT)
- BP-25712
- $129,031.00 (11/01/2011 - 04/16/2014) Hoffman La-Roche Ltd.
- PI - A multicenter, randomized, double blind, placebo controlled parallel group study to investigate the efficacy and safety of RO4005819 versus placebo, as adjunctive therapy in patients with major depressive disorder having inadequate response to ongoing antidepressant treatment
- CN-162-010
- $73,737.00 (07/01/2011 - 01/15/2014) Bristol-Myers Squibb Company
- PI - A multicenter, randomized, double-blind 58 week rollover study to assess the safety and tolerability of BMS-820836 in patients with treatment-resistant major depression. BCM IRB Protocol # H-29010
- CN-162-007
- $207,285.00 (07/01/2011 - 12/10/2013) Bristol-Myers Squibb Company
- PI - Multi-center, randomized, double-blind, active-controlled, comparative, fixed-dose, dose-response study of the efficacy and safety of BMS-820836 in patients with treatment-resistant major depression. BCM IRB Protocol # H-28942
- Efficacy and Tolerability of Riluzole in Treatment Resistant Depression
- $750,000.00 (08/01/2010 - 07/31/2014) R01MH085054
- CO-PI - The goal of this 4-site NIH collaborative R01 is to study the efficacy and safety of the glutamate modulator riluzole in patients with treatment-resistant depression and to investigate biomarkers predictive of response. BCM IRB Protocol # H-26581
- EVT 101/102
- $198,872.00 (07/01/2010 - 03/31/2011) Evotec Neurosciences GmbH
- PI - A 4-Week, Randomized, Double-blind, Parallel-Group Placebo-Controlled Study to Investigate the Safety and Efficacy of EVT 101 as Monotherapy in Patients With Treatment-Resistant Major Depression. This proof-of-concept 4-week placebo-controlled multicenter trial tests the safety and efficacy of an oral NR2B antagonist in patients with treatment-resistant depression. BCM IRB Protocol # H-26893
- JNJ2648911MDD2001
- $71,109.00 (07/01/2010 - 01/31/2012) Johnson & Johnson
- PI - A Randomized, Double Blind, Parallel-Group, Active-and Placebo-Controlled Study to Assess the Efficacy and Safety of JNJ-26489112 in Adult Subjects with Major Depressive Disorder. BCM IRB Protocol # H-26841
- Adjunctive IV Ketamine in Treatment-Resistant Depression - #NARSAD Grant (09/15/2009 - 09/14/2012) The Brain and Behavior Research Fund
- Co-PI - The goal of this randomized controlled trial is to test the safety, efficacy, and time-to-response of repeated dose intravenous Ketamine as adjunctive therapy to a SSRI for severely symptomatic patients with MDD. BCM IRB Protocol # H-26488
- Optimization of IV Ketamine for Treatment Resistant Major Depression
- $1,064,832.00 (07/23/2009 - 12/17/2015) NIMH - RO1MH081870-01A2
- Co-PI - The goal of this study is to test the safety, tolerability, and acute efficacy of a single subanesthetic dose of intravenous Ketamine in patients with treatment-resistant major depressive disorder, using a randomized, triple-blind, midazolam-controlled, parallel-arm design. BCM IRB Protocol # H-26303
- Corcept - #BCM IRB #H- 49885
- $208,558.50 (07/21/2021 - 07/21/2022) Grant funding from CORT118335-876 (GRATITUDE)
- A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Safety, Efficacy, and Pharmacokinetics of Miricorilant (CORT118335) in Obese Adult Patients with Schizophrenia or Bipolar Disorder and Recent Weight Gain While Taking Antipsychotic Medications
- Corcept - #BCM IRB # H- 49803
- $198,646.00 (06/28/2021 - 06/21/2022) Grant funding from CORT118335-877 (GRATITUDE II)
- A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Safety, Efficacy, and Pharmacokinetics of Miricorilant in Obese Adult Patients with Schizophrenia Taking Antipsychotic Medications
- F. Hoffman-LaRoche Ltd - #BCM IRB #H- 49048
- $244,250.72 (06/24/2021 - 06/24/2024) Grant funding from BP40283
- Phase 2, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Effects Of RO6889450 (RALMITARONT) In Patients with Schizophrenia or Schizoaffective Disorder and Negative Symptoms
- VistaGen Therapeutics, Inc - #BCM IRB #H- 49953
- $119,394.00 (06/09/2021 - 04/28/2022) Grant funding from PH94B-CL-026
- A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled Clinical Trial of PH94B Nasal Spray for the Acute Treatment of Anxiety Induced by a Public Speaking Challenge in Adult Subjects with Social Anxiety Disorder (PaliSADe-1)
- ACADIA - #BCM IRB #H- 49708
- $202,879.49 (05/19/2021 - 11/19/2022) Grant funding from ACP-103-063
- 16-Week Open-Label Study of the Effects of Treatment with Pimavanserin on Activities of Daily Living in Subjects With Parkinson’s Disease Psychosis
- Alkermes - #BCM IRB Protocol # H-43721
- $101,502.00 (02/10/2021 - 03/08/2022) Grant funding from ALKS3831- A307
- A Study to evaluate the effect of ALKS 3831 compared to Olanzapine on body weight in young adults with the Schizophrenia, Schizophreniform, or Bipolar I Disorder I who are early in their illness.
- Biosciences, LTD - #BCM IRB Protocol # H-48253
- $43,540.00 (08/27/2020 - 07/20/2022) Grant funding from CLE100-MDD-201 CLEXIO
- A Two-part Study of CLE-100 as an Adjunct Therapy in Subjects with Major Depressive Disorder
- NIHCo - #Protocol # H-46685 (04/13/2020 - 02/09/2022) Grant funding from DBS Study
- Leveraging Ethical Dissension among Capacity, Beneficence and Justice in Clinical Trials Neurotherapeutics in the Severely Disabled: Lessons from Schizophrenia BCM IRB
- Karuna Therapeutics - #BCM IRB #H-55189
- $285,000.00 (06/23/2024 - 07/26/2025) KAR-012
- A Phase 3, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Safety and Efficacy of Adjunctive KarXT in Subjects with Inadequately Controlled Symptoms of Schizophrenia
- L- Study Click Therapeutic, Inc. - #BCM IRB #H- 55650
- $150,603.00 (07/10/2024 - 07/10/2025) Convoke
- A Single-Arm, Open Label, 16-Week Extension Study To Evaluate The Efficacy And Safety Of A Second Course Of A Digital Therapeutic (CT-155) As An Adjunct To Standard Of Care Antipsychotic Therapy In Adult And Late Adolescent Participants With Experiential Negative Symptoms Of Schizophrenia
- Karuna Therapeutics - #BCM IRB #H-55669
- $300,000.00 (07/24/2024 - 07/24/2025) KAR-013
- An Open-label Extension Study to Assess the Long-term Safety and Tolerability of Adjunctive KarXT in Subjects with Inadequately Controlled Symptoms of Schizophrenia
- Tonix Pharmaceuticals, Inc Sub-I - #BCM IRB #H- 53804
- $110,164.00 (01/19/2024 - 01/24/2025) TNX-CE-CI202
- A Single-Blind, Randomized Study Comparing the Efficacy and Safety of a Single Dose of TNX-1300 to Placebo with Usual Care (UC) for the Treatment of Signs and Symptoms of Acute Cocaine Intoxication in Emergency Department (ED) Subjects
- Relmada Therapeutics, Inc. Sub -I - #BCM IRB #H- 54122
- $174,263.00 (12/20/2023 - 11/30/2025) RELIGHT Study
- Randomized, Double-Blind, Placebo-Controlled Trial of REL-1017 as an Adjunctive Treatment for Major Depressive Disorder
- Neurocrine Biosciences, Inc. - #BCM IRB #H- 53590 (08/08/2023 - 02/16/2025) NBI-98854-TD4020
- A Phase 4, Single-Arm, Open-Label Study to Evaluate the Effectiveness of Valbenazine on Patient- and Clinician-Reported Outcomes in Subjects With Tardive Dyskinesia
- Click Therapeutic, Inc - #BCM IRB # H-53368
- $102,573.00 (05/12/2023 - 08/20/2025) CONVOKE Study
- A Multicenter, Randomized, Double-Blind, Parallel-Group, Controlled, 16-week Study to Evaluate the Efficacy and Safety of a Digital Therapeutic (CT-155) as an Adjunct to Standard-of-Care Antipsychotic Therapy in Adult and Late Adolescent Participants with Experiential Negative Symptoms of Schizophrenia
- Navitor Pharmaceuticals, Inc - #BCM IRB # H-51058 (03/07/2022 - 11/10/2024) NAV-17A-007
- A Phase 2, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of NV-5138 in Adults with Treatment Resistant Depression
- Boehringer Ingelheim - #BCM IRB # H-49447
- $119,394.00 (11/22/2021 - 04/17/2025) Connex 3
- A Phase III Randomized, Double-Blinded, Placebo- Controlled Parallel Group Trial to Examine the Efficacy and Safety of Bi 425809 Once Daily Over 26 Week Treatment Period in Patients with Schizophrenia
- NIHCo - #BCM IRB Protocol # H-46685 (04/13/2020 - 12/12/2024) DBS Study
- Leveraging Ethical Dissension among Capacity, Beneficence and Justice in Clinical Trials Neurotherapeutics in the Severely Disabled: Lessons from Schizophrenia
- Long Term Follow Up of Affective Disorder Patients (04/19/2010 - 10/26/2026) BCM IRB Protocol # H-26242
- Screening and long-term 5-year naturalistic cohort study collecting clinical data on Subjects with primary mood disorders
Log In to edit your profile
